32 results about "Blocking drug" patented technology

A method of treating and reducing a drug dependency such as a nicotine dependency is provided. The method comprises initially administering to a subject a drug, such as nicotine or another agonist of the drug in an amount which would normally provide the desired pharmacologic effects and at least partially satiate the needs for the drug by a user. The method also comprises administering to the subject an antagonist to the drug or its other agonist in an amount sufficient to at least partially block the pharmacologic defects of the drug or its other agonist while there is a substantial amount of the drug or other agonist present in the system of the user. In one embodiment of the invention, the drug and the antagonist are administered substantially simultaneously so as to occupy a substantial portion of the receptors of the user for that drug thereby blocking or attenuating the effects of any further intake of the drug or other agonist. In another embodiment, the drug or its other agonist is first administered and the antagonist is self-administered by a subject in a manner which mimics the use of the drug thereby counter-conditioning the drug user to the stimuli associated with the normal administration of the drug. The invention further provides a method of therapeutically treating psychophysiologic diseases and disorders involving neuronal dysregulation. The method additionally provides a pharmacologic composition for the treatment and reduction of drug dependence and which relies upon a combination of an agonist and antagonist.

Cholesterol-uptake-blocking drugs inhibit angiogenesis and are useful to inhibit diseases perpetuated by angiogenesis. Cholesterol reduction with the use of the drugs increases the intratumoral level of thrombospondin-1, an angiogenesis inhibitor. Ezetimibe (Zetia®), a specific cholesterol-uptake blocking drug, also retards the growth of human tumors, most preferably in combination with low-cholesterol diet. The pharmacologic reduction in serum cholesterol retards prostate cancer growth by inhibiting tumor angiogenesis to combat the growth of prostatic tumors which are directly accelerated by hypercholesterolemia.

The invention relates to the technical field of automatic drug selling, in particular to an automatic drug selling pharmacy precise in drug feeding. The drug selling pharmacy comprises a rack, a plurality of combined chambers for storing drugs are fixed to the rack, each combined chamber comprises a plurality of oblique chamber bodies, blocking pieces for blocking drug boxes are arranged at the bottoms of the chamber bodies, and a drug feeding and conveying machine is arranged outside the rear portion of the rack; a drug feeding module is arranged in the rear portion of the rack, and a drug feeding mechanism is slidably arranged on the drug feeding module, conveys the drug boxes from the drug feeding and conveying machine to the chamber bodies and comprises a U-shaped groove plate and a first slideway located above the U-shaped groove plate; an included angle between the bottom edge of the cross section of the first slideway and the horizontal direction is greater than 0 degree, a first side plate and a second side plate are disposed on the two sides of the first slideway respectively and both are perpendicular to the bottom face of the first slideway, the first side plate is lowerthan the second side plate, and a first side edge of the upper end of the first side plate and a second side edge of one side of the bottom of the corresponding chamber body are parallel to each other and aligned in the vertical direction. The drug selling pharmacy is accurate in drug feeding.

The invention relates to a calcium channel blocking drug molecule co-crystal and a preparation method thereof. The general molecular formula of the calcium channel blocking drug molecule co-crystal is(C20H25ClN2O5).(X).((CH3)2CHOH)n, wherein X represents one of benzene sulfonic acid, maleic acid and fumaric acid; and n represents the number of isopropanol molecules, and n is greater than 0 and less than and equal to 1. A co-crystal drug provided solves the solubility and stability problems of existing levamlodipine, and is beneficial to the improvement of the stability of levamlodipine tablets, preparation of the co-crystal is simple, the cost is low, the crystal form of the prepared crystal is regular, the particle size is uniform, and industrial production prospects are achieved.

The present disclosure provides methods for alleviating or preventing the negative physiological side effects associated with the administration of EGFR blocking therapeutics. The disclosure provides, inter alia, methods for treating or preventing: hypomagnesemia, cardiac dysfunction, and skin lesions, which are induced by EGFR blocking drugs, by administering an NK-1 receptor antagonist.

The invention relates to a method for inducing a rapid eye movement sleep behavior disorder (RBD) phenotype capable of transforming to a Parkinson phenotype in a non-human subject animal. The method comprises the following steps: 1) stereotactically injecting a substance capable of inducing a pathological change of synuclein into a unilateral or bilateral mesocephalon sublaterodorsal tegmental nucleus (SLD) of a non-human subject animal; 2) evaluating the induction of the RBD phenotype of the non-human tested animal; and 3) evaluating the induction of the Parkinson phenotype in the RBD animal. The invention also relates to a preparation method of a synuclein pathological RBD model. Prefabricated fibrous bodies (PFFs) capable of inducing synuclein pathology is stereodirectionally injected into an SLD nucleus, a mouse RBD model capable of transforming to a Parkinson phenotype is constructed by virtue of a pathology induction characteristic of "dissemination-nucleation" of the fibrous bodies, and the model is expected to provide an important animal model basis for clarification of pathogenesis and Parkinson's disease transforming of RBD and research and development of effective blocking drugs in a future research.

The invention discloses a catheter for clinical intravascular interventional treatment. The catheter for clinical intravascular interventional treatment comprises a filling pipe. A filling pipe limiting structure is arranged in the middle of the filling pipe. A connection catheter seat is arranged on the outer surface of one end of the filling pipe. The outer surface of one end of the connection catheter seat is fixedly connected with a second connection catheter opening, a protection and antifouling structure is arranged on the outer surface of one end of the second connection catheter opening, a connection outer-pipe is arranged on the outer surface of the other end of the filling pipe, an inflatable bone tamp is arranged on the outer surface of one end of the connection outer-pipe, anda catheter body is arranged on the outer surface of the front end of the inflatable bone tamp. According to the catheter for clinical intravascular interventional treatment, the filling pipe limitingstructure is arranged so that the position of the filling pipe can be limited, and the work of medical staff is prevented from being obstructed; an anti-blocking drug injection device is arranged so that the impact of an injected drug on blood vessels can be avoided, and a patient is prevented from feeling uncomfortable; and the protection and antifouling structure is arranged, the sanitation of an end opening of the catheter is conveniently ensured, and the next use is facilitated.

A method for the fail-safe termination of in vivo drug delivery from an implantable drug delivery system, the method comprising: providing an implantable drug delivery system comprising: a housing having a reservoir for containing a drug, and a port for dispensing the drug to a patient; and an emergency deactivation unit disposed between the reservoir and the port, the emergency deactivation unit comprising a composite structure comprising a biocompatible ferromagnetic mesh open to fluid flow and a hydrophobic meltable material, the hydrophobic meltable material comprising at least one hole therein for enabling a fluid to pass through the hydrophobic meltable material; implanting the implantable drug delivery system within a patient; enabling the drug to flow from the reservoir, through the at least one hole in the hydrophobic meltable material and out the port; and when drug flow is to be terminated, applying a magnetic field to the composite structure, such that a current is induced in the ferromagnetic mesh which heats the ferromagnetic mesh and melts the hydrophobic meltable material, thereby closing the at least one hole in the hydrophobic meltable material and blocking drug delivery to the patient.

The invention relates to an H2 receptor blocking drug efficacy related gene SLC22A1 polymorphism detection kit, comprising a test tube separately provided with each C1022T detection primer and each internal control gene detection primer, wherein the C1022T detection primer comprises the following sequence components: C1022T detection primer 1: 5'-GCAGACCTGT TCCGCACGTC-3'; C1022T detection primer 2: 5'-CAGACCTGTT CCGCACGAT-3'; C1022T detection primer 3: 5'-CACTCACAAC TATATTACA-3'; the internal control gene detection primer comprises the following sequence components: internal control primer 1:5'-AGCAAGCAGG AGTATGACG-3'; internal control primer 2: 5'-GAAAGGGTGT AACGCAACT-3'. Compared with the prior art, the kit has the advantages of high sensitivity, high specificity and short time consumption when the SLC22A1 gene mutation of samples such as fresh blood is detected.

The invention belongs to the technical field of medicine carrying platforms, and particularly relates to a multifunctional composite stent and a preparation method and application thereof. Wherein the multifunctional composite stent has the characteristic of programmed release of therapeutic drugs, the tumor vascular blocking drugs loaded on the stents on the two sides can preferentially and rapidly release and damage tumor tissue vascular endothelial cells so as to cause necrosis of part of cancer cells in the tumor, and then the intermediate electrostatic spinning membrane releases chemotherapeutic drugs permanently, so that the tumor tissue vascular endothelial cells are damaged. The degradable electrostatic spinning membrane loaded with the chemotherapy drug can act on residual tumor cells for a long time, effectively kills the residual tumor cells and reduces the tumor recurrence rate, and the biocompatible stent loaded with the tumor blood vessel blocking drug is overlaid on the two sides of the degradable electrostatic spinning membrane loaded with the chemotherapy drug to form a sandwich structure; the technical problems that residual tumor cells are difficult to effectively kill and the tumor recurrence rate is high in the prior art are solved.

The invention relates to the technical field of medicine. Jellyfish stings are the most common marine injury worldwide, and acute circulatory failure caused by cardiovascular toxic components in jellyfish toxins is considered to be the main cause of death from jellyfish stings. The present invention also provides the application of different types of adrenergic receptor blocking drugs in the preparation of jellyfish toxin cardiotoxic antagonist drugs, and the different types of adrenergic receptor blocking drugs refer to α receptor blocking drugs, β receptor blocking drugs And α, β receptor blockers, especially non-selective α receptor blockers, non-selective β receptor blockers, selective long-acting β1 receptor blockers, selective short-acting β1 receptor blockers body blockers. The present invention finds that different types of adrenergic receptor blocking drugs can effectively antagonize the cardiotoxicity of jellyfish toxins at the three levels of cultured suckling rat cardiomyocytes, isolated hearts and whole animals, and can be developed as a preventive or therapeutic drug for jellyfish stings .

The invention relates to a laboratory article, in particular to a combined medicinal spoon structure for taking drugs. The combined medicinal spoon comprises a spoon head and a handle detachably connected to the spoon head. The combined medicinal spoon is characterized in that: the spoon head comprises a square drug taking structure, a plug that is fixedly connected to the square drug taking structure to connect the handle, and a baffle plate plugged to the square drug taking structure. The combined medicinal spoon provided by the invention adopts a square head design and very thin edge, and also has an auxiliary baffle plate specially for blocking drugs so as to conveniently take redundant drugs out and taking drugs from a balance, and also the problems of error brought about by to-and-fro movement of weighing paper and sprinkling of drugs inside the balance can be avoided.

The invention discloses new application of rapamycin in inhibiting propagation of plasmodium by entomoplily. The new application is characterized in that the rapamycin is used for decreasing the number of plasmodium oocysts in an entomoplily body; the rapamycin is used for improving the antiplasmodial infection ability of the entomoplily; and the rapamycin is used for improving the expression level of immune effector molecules TEP1 of the entomoplily. The invention also discloses application of the rapamycin in preparation of a reagent for inhibiting the propagation of the plasmodium by the entomoplily and a special preparation. It is discovered that the rapamycin can improve the ability of resisting mosquito infection by improving the expression level of PET-1, can achieve the purposes ofdecreasing the number of the plasmodium oocysts in the entomoplily body and effectively inhibiting the propagation of the plasmodium by anopheles, and the rapamycin can be used as a blocking drug ofthe propagation of the plasmodium by the mosquitoes.